Brand vs. Compounded Semaglutide: Safety, Efficacy, and Risks

Last Updated: March 2026

When considering semaglutide for weight management or type 2 diabetes, patients face a critical choice: FDA-approved brand-name medications like Wegovy and Ozempic, or less expensive, compounded versions. This distinction carries profound implications for safety, efficacy, and legal standing. In the landmark STEP 1 trial, semaglutide (Wegovy) delivered an average 14.9% body weight loss compared to 2.4% for placebo over 68 weeks, establishing a clear efficacy benchmark for the approved drug (Wilding et al., 2021). No such rigorous clinical trial data exists for compounded semaglutide.

The rise of compounded semaglutide stemmed directly from persistent drug shortages of the FDA-approved products, particularly from late 2022 through 2024. While these shortages have eased for some doses, the availability of compounded alternatives continues to pose a challenge to patient safety and regulatory integrity. Understanding the fundamental differences between these options is paramount for informed decision-making.

Understanding Semaglutide: The FDA-Approved Standard

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the natural hormone GLP-1, which regulates blood sugar by increasing insulin release, suppressing glucagon secretion, slowing gastric emptying, and promoting a feeling of fullness. These actions make it highly effective for both managing type 2 diabetes and promoting significant weight loss.

Two main FDA-approved injectable semaglutide products are on the market:

• Ozempic (semaglutide injection): Approved by the FDA in 2017 for improving blood sugar control in adults with type 2 diabetes and reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is often used off-label for weight loss, but its approval is not for this indication.
• Wegovy (semaglutide injection): Approved by the FDA in 2021 specifically for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia).

Both Ozempic and Wegovy contain semaglutide base as their active pharmaceutical ingredient. They are manufactured under stringent quality control standards, undergo extensive clinical trials to prove their safety and efficacy, and are subject to continuous post-market surveillance by the FDA.

What is Compounding? The Regulatory Nuances

Drug compounding is the process by which a licensed pharmacist or a physician combines, mixes, or alters ingredients to create a medication tailored to the needs of an individual patient. This practice is legally permissible under specific circumstances outlined in the Drug Quality and Security Act (DQSA) of 2013. Traditionally, compounding addresses patient-specific needs such as allergies to inactive ingredients, dosage forms not commercially available, or when a drug is on the FDA’s official drug shortage list.

The key legal caveat for compounding a drug that is essentially a copy of an FDA-approved drug is that the finished product must be on the FDA’s drug shortage list. Both Ozempic and Wegovy have been on this list at various times, particularly in their higher doses, which initially opened the door for compounding pharmacies to produce alternatives. Notably, the American Journal of Managed Care (AJMC) highlighted in a 2023 article that both Wegovy and Ozempic were on the FDA drug shortages list until February 2025 for certain dose presentations, directly impacting the landscape for compounded versions (AJMC, 2023).

However, a critical distinction arises: compounded drugs are not FDA-approved. This means they do not undergo the agency’s rigorous pre-market evaluation for safety, efficacy, and quality.

The Key Differences: Brand vs. Compounded Semaglutide

The differences between FDA-approved semaglutide and compounded versions are not merely about packaging or price; they are fundamental to the drug’s composition, manufacturing, and regulatory oversight.

Active Ingredient Identity and Purity

• FDA-Approved Semaglutide (Wegovy, Ozempic): These products contain semaglutide base, the precise molecule that underwent all the clinical trials for safety and efficacy. Its purity and identity are meticulously controlled.
• Compounded Semaglutide: Many compounded semaglutide products utilize semaglutide salts, such as semaglutide sodium or semaglutide acetate. These are not the same active ingredient as the semaglutide base found in FDA-approved products. The FDA has explicitly warned about this, stating: “FDA is aware that some compounders may be using semaglutide salts, such as semaglutide sodium and semaglutide acetate. FDA’s understanding is that semaglutide base is the active ingredient in Ozempic and Wegovy. The agency has not reviewed the safety or efficacy of compounded drugs containing these other semaglutide salts” (FDA, 2023). The pharmacokinetic and pharmacodynamic profiles of these salts, and how they behave in the human body compared to semaglutide base, remain unknown and unstudied.

Manufacturing and Quality Control

• FDA-Approved Semaglutide: Manufactured in facilities that adhere to strict Current Good Manufacturing Practices (CGMPs). These standards ensure consistent quality, purity, potency, and sterility of every batch. Processes are validated, ingredients are sourced from approved suppliers, and final products undergo extensive testing.
• Compounded Semaglutide: While compounding pharmacies must follow some state-level regulations and USP (United States Pharmacopeia) guidelines for compounding, these are significantly less stringent than CGMPs. There is less oversight over raw material sourcing, sterility testing (especially for injectable products), and overall quality control. A review of the FDA’s freight database found that 239 semaglutide and tirzepatide shipments—many intended for compounding—were produced at unregistered factories, facilities that the agency hasn’t inspected (Scientific American, 2023). This significantly elevates the risk of contamination, incorrect potency, and adulteration.

Clinical Trials and Efficacy Data

• FDA-Approved Semaglutide: Backed by extensive, multi-phase clinical trials involving thousands of patients. These trials establish precise efficacy rates, common side effects, and long-term safety profiles. The 14.9% weight loss observed with Wegovy is a direct result of this rigorous testing.
• Compounded Semaglutide: There are no clinical trials supporting the efficacy or safety of specific compounded semaglutide formulations. Any perceived efficacy relies on the assumption that the compounded product behaves identically to the FDA-approved version, an assumption undermined by the use of different active ingredients (salts vs. base) and varied formulations.

Regulatory Oversight and Safety Monitoring

• FDA-Approved Semaglutide: Subject to ongoing post-market surveillance by the FDA. Manufacturers are required to report adverse events, and the FDA monitors these reports to identify potential new safety concerns.
• Compounded Semaglutide: Oversight is primarily at the state board of pharmacy level. While pharmacies are inspected, these inspections typically focus on compliance with compounding regulations rather than comprehensive drug safety and efficacy evaluation. Adverse events with compounded drugs may not be consistently reported to a central database, making it difficult to detect widespread safety issues.

Safety Risks of Compounded Semaglutide

The lack of FDA oversight and the variability in manufacturing processes introduce several significant safety risks with compounded semaglutide:

1. Unknown Ingredients: The use of semaglutide salts, which are not the active ingredient in approved products, means patients are receiving a drug with an uncharacterized pharmacological profile. This could lead to unpredictable effects, reduced efficacy, or novel side effects not seen with the FDA-approved semaglutide base.
2. Contamination and Sterility Issues: For injectable compounded products, the risk of bacterial or fungal contamination is a serious concern. If prepared in non-sterile environments or with improperly sterilized equipment, these products can cause severe infections, abscesses, or systemic illness.
3. Incorrect Potency: Compounding errors can lead to medication that is either too strong (overdosing) or too weak (underdosing). Overdosing can result in severe gastrointestinal side effects (nausea, vomiting, diarrhea), hypoglycemia, or other adverse reactions. Underdosing renders the medication ineffective, wasting patient time and money.
4. Allergic Reactions and Adverse Events: Compounded products may contain different inactive ingredients (excipients) than the FDA-approved versions. Patients could experience allergic reactions or adverse effects to these untested components.
5. Lack of Recourse: If an adverse event occurs with a compounded drug, the path for investigation and accountability is far less clear than with an FDA-approved product, where a clear manufacturing chain of custody and reporting structure exists.

The FDA’s stance is unequivocal: “Patients should not use compounded drugs if an FDA-approved drug is available to treat a patient’s condition.” They also strongly advise against using compounded semaglutide products that claim to be identical to Ozempic or Wegovy, especially those containing semaglutide salts, due to the lack of safety and efficacy data (FDA, 2023).

Efficacy Considerations

For FDA-approved semaglutide, efficacy is proven. Trials like STEP 1 and STEP 3 demonstrated average total body weight loss of 14.9% and 16.0% respectively at 68 weeks with Wegovy 2.4 mg (Wilding et al., 2021). Ozempic has likewise shown significant HbA1c reductions and moderate weight loss in its diabetes trials.

For compounded semaglutide, efficacy is speculative. Without controlled clinical trials on the specific compounded formulations, there is no guarantee that the patient will achieve the same results as with the FDA-approved drug. Inconsistent potency, differing active ingredients, and varying absorption rates due to different excipients can all contribute to suboptimal or unpredictable outcomes. Patients may pay for a product that simply does not work as intended.

Regulatory Landscape and Legal Status

The FDA has been increasingly active in addressing the proliferation of unauthorized compounded GLP-1 agonists. The agency has issued multiple warning letters to pharmacies and providers involved in illegal compounding or marketing of these drugs.

The legality of compounding semaglutide relies heavily on the official FDA drug shortage list. When Ozempic and Wegovy are not on this list for a specific strength, compounding pharmacies are prohibited from compounding a version that is essentially a copy of the approved drug. Even when a drug is on the shortage list, compounded versions must adhere to certain quality and ingredient standards, which many compounded semaglutide products (particularly those using salts) fail to meet.

Comparison: FDA-Approved vs. Compounded Semaglutide

The table below summarizes the critical differences between brand-name, FDA-approved semaglutide and its compounded counterparts.

Conclusion

The distinction between FDA-approved semaglutide and compounded versions is not trivial. It represents a fundamental difference in patient safety, proven efficacy, and regulatory assurance. While the appeal of lower cost and greater availability for compounded options is understandable, especially in the context of drug shortages, the risks associated with unapproved ingredients, inconsistent manufacturing quality, and the absence of rigorous clinical data are substantial.

Patients seeking semaglutide for weight management or diabetes treatment are best served by FDA-approved medications, which provide a predictable and extensively studied safety and efficacy profile. The FDA’s clear warnings against compounded semaglutide, particularly those using semaglutide salts, should give any patient or provider serious pause. Choosing an FDA-approved product ensures that the medication you are injecting or consuming has met the highest standards for quality, safety, and effectiveness.

Sources

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. U.S. Food & Drug Administration. (2023, May 31). Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. FDA News Release. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
3. American Journal of Managed Care. (2023, November 28). Navigating Compounded Semaglutide: What Health Care Providers Need to Know. AJMC. [https://www.ajmc.com